Get notified when QDEL files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRisk Profile Improvements
- Revenue Guidance Narrowed To Low End With Conditional Assumptions (new) — Management's full-year outlook explicitly excludes prolonged China reimbursement pressure or extended Middle East conflict, creating downside risk if either condition persists.
- Multiple Simultaneous Headwinds (new) — The Q1 miss stems from three concurrent issues (weak respiratory season, China slowdown, EMEA delays), raising questions about whether management can offset all three in remaining quarters.
QuidelOrtho pre-announces Q1 revenue miss at $615-620M, cuts full-year outlook to low end
Filed April 15, 2026 · Period ending April 15, 2026 · ~1 min read
Key Changes
-
high
Q1 2026 revenue of $615-620M falls short of prior guidance, driven by 30% drop in U.S. flu visits, China distributor slowdown tied to proposed reimbursement cuts, and Middle East conflict delays in EMEA.
Exhibit 99.1 verify on EDGAR → -
high
Management narrows full-year 2026 guidance to the low end of prior range, warning that outlook assumes no prolonged China reimbursement headwinds or extended Middle East disruptions.
Exhibit 99.1 verify on EDGAR → -
medium
Q1 free cash flow expected at negative $65-70M, consistent with prior first-half burn guidance; full-year 2026 free cash flow still expected positive.
Exhibit 99.1 verify on EDGAR →
1 more material change behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (FRVO 10-Q) is open in full — no account needed.
Partner
Trade QDEL commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Generated by AI · Jun 26, 2026 12:54 AM